Literature DB >> 24388729

A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy.

Keith G Rasmussen1, Simon Kung2, Maria I Lapid2, Tyler S Oesterle2, Jennifer R Geske3, Gregory A Nuttall4, William C Oliver4, John P Abenstein4.   

Abstract

To assess the clinical utility of ketamine as an anesthetic agent for electroconvulsive therapy (ECT), based upon recent findings that ketamine may have antidepressant properties. Depressed ECT patients were randomly assigned to receive anesthesia with either ketamine or methohexital. Outcome measures included assessments of depressive severity, cognition, post-anesthesia side effects, and hemodynamics. Twenty one patients were treated with ketamine and 17 with methohexital. There were no significant differences in depression or cognitive outcomes between the two drugs. Additionally, there were no measures of post-anesthesia tolerability or hemodynamics which favored ketamine. Ketamine anesthesia does not accelerate the antidepressant effect of ECT or diminish the cognitive side effects, at least as measured in this study. Furthermore, there is no apparent benefit of ketamine for speed or quality of post-ECT recovery, and it is associated with higher systolic blood pressures after the treatments. Ketamine is associated with longer motor seizure duration than methohexital.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Anesthesia; Cognition; Hemodynamics; Major depression; Mood disorder

Mesh:

Substances:

Year:  2013        PMID: 24388729     DOI: 10.1016/j.psychres.2013.12.027

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  18 in total

Review 1.  Ketamine enantiomers in the rapid and sustained antidepressant effects.

Authors:  John Muller; Sahana Pentyala; James Dilger; Srinivas Pentyala
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-10

2.  Post-electroconvulsive therapy recovery and reorientation time with methohexital and ketamine: a randomized, longitudinal, crossover design trial.

Authors:  Tony Yen; Mohamad Khafaja; Nicholas Lam; James Crumbacher; Ronald Schrader; John Rask; Mary Billstrand; Jacob Rothfork; Christopher C Abbott
Journal:  J ECT       Date:  2015-03       Impact factor: 3.635

3.  A Randomized Pilot Study Comparing Ketamine and Methohexital Anesthesia for Electroconvulsive Therapy in Patients With Depression.

Authors:  Shona L Ray-Griffith; Lou Ann Eads; Xiaotong Han; Kimberly Golden; Zachary N Stowe
Journal:  J ECT       Date:  2017-12       Impact factor: 3.635

4.  S -ketamine compared to etomidate during electroconvulsive therapy in major depression.

Authors:  Maxim Zavorotnyy; Ina Kluge; Kathrin Ahrens; Thomas Wohltmann; Benjamin Köhnlein; Patricia Dietsche; Udo Dannlowski; Tilo Kircher; Carsten Konrad
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-04-19       Impact factor: 5.270

5.  Next-Step Treatment Considerations for Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine.

Authors:  William V Bobo; Patricio Riva-Posse; Fernando S Goes; Sagar V Parikh
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-04-23

6.  Speed of response to electroconvulsive therapy compared with ketamine.

Authors:  Charles H Kellner; Sarah H Lisanby; Richard Weiner; Joan Prudic; Matthew V Rudorfer; Robert C Young; George Petrides; W Vaughn McCall; Mustafa Husain; Robert M Greenberg; Rebecca G Knapp
Journal:  Psychiatry Res       Date:  2015-01-30       Impact factor: 3.222

Review 7.  Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.

Authors:  Rebecca L Dean; Claudia Hurducas; Keith Hawton; Styliani Spyridi; Philip J Cowen; Sarah Hollingsworth; Tahnee Marquardt; Annabelle Barnes; Rebecca Smith; Rupert McShane; Erick H Turner; Andrea Cipriani
Journal:  Cochrane Database Syst Rev       Date:  2021-09-12

8.  Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression (Ketamine-ECT study).

Authors:  Liam Trevithick; R Hamish McAllister-Williams; Andrew Blamire; Tim Branton; Ross Clark; Darragh Downey; Graham Dunn; Andrew Easton; Rebecca Elliott; Clare Ellwell; Katherine Hayden; Fiona Holland; Salman Karim; Jo Lowe; Colleen Loo; Rajesh Nair; Timothy Oakley; Antony Prakash; Parveen K Sharma; Stephen R Williams; Ian M Anderson
Journal:  BMC Psychiatry       Date:  2015-10-21       Impact factor: 3.630

9.  Medication management during electroconvulsant therapy.

Authors:  Monica Zolezzi
Journal:  Neuropsychiatr Dis Treat       Date:  2016-04-19       Impact factor: 2.570

10.  Intravenous theophylline is the most effective intervention to prolong EEG seizure duration in patients undergoing electroconvulsive therapy.

Authors:  Alexander Tzabazis; Michaela E Wiernik; Jan Wielopolski; Wolfgang Sperling; Harald Ihmsen; Hubert J Schmitt; Tino Münster
Journal:  BMC Anesthesiol       Date:  2017-08-29       Impact factor: 2.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.